RELATIONSHIP BETWEEN THE MUTATION OF P53 GENE AND INFILTRATION，METASTASIS AND PROGNOSIS OF GASTRIC CARCINOMA

ＲＥＬＡＴＩＯＮＳＨＩＰＢＥＴＷＥＥＮＴＨＥＭＵＴＡＴＩＯＮＯＦＰ５３ＧＥＮＥＡＮＤＩＮＦＩＬＴＲＡＴＩＯＮ，ＭＥＴＡＳＴＡＳＩＳＡＮＤＰＲＯＧＮＯＳＩＳＯＦＧＡＳＴＲＩＣＣＡＲＣＩＮＯＭＡＸｉｎＹａｎ辛彦；ＺｈａｏＦｅｎｇｋａｉ赵凤凯；ＷｕＤｏｎｇ...     

RESEARCH ON SERUM LEVELS OF RETINOL，α－TOCOPHEROL β－CAROTENE，AND 12 ELEMENTS IN GASTRIC DYSPLASIA AND GASTRIC CANCER PATIENTS

ＲＥＳＥＡＲＣＨＯＮＳＥＲＵＭＬＥＶＥＬＳＯＦＲＥＴＩＮＯＬ，α－ＴＯＣＯＰＨＥＲＯＬβ－ＣＡＲＯＴＥＮＥ，ＡＮＤ１２ＥＬＥＭＥＮＴＳＩＮＧＡＳＴＲＩＣＤＹＳＰＬＡＳＩＡＡＮＤＧＡＳＴＲＩＣＣＡＮＣＥＲＰＡＴＩＥＮＴＳＣｈｅｎｇＷｕｆｅｎｇ；程五凤；...     

QUALITATIVE STUDY OF SIALOMUCINS CHANGES DURING N－METHYL－N－NITROSOUREA－INDUCED C OLONIC CARCINOGENESIS IN MICE

ＱＵＡＬＩＴＡＴＩＶＥＳＴＵＤＹＯＦＳＩＡＬＯＭＵＣＩＮＳＣＨＡＮＧＥＳＤＵＲＩＮＧＮ－ＭＥＴＨＹＬ－Ｎ－ＮＩＴＲＯＳＯＵＲＥＡ－ＩＮＤＵＣＥＤＣＯＬＯＮＩＣＣＡＲＣＩＮＯＧＥＮＥＳＩＳＩＮＭＩＣＥＷａｎｇＱｉａｎｇ王强；ＷａｎｇＹｕａｎｈｅ王元和；...     

ISOLATION AND CHARACTERIZATION OF AN ADRIAMYCIN－RESISTANT SUBLINE OF THE HUMAN GASTRIC ADENOCARCINOMA CELLLINE

ＩＳＯＬＡＴＩＯＮＡＮＤＣＨＡＲＡＣＴＥＲＩＺＡＴＩＯＮＯＦＡＮＡＤＲＩＡＭＹＣＩＮ－ＲＥＳＩＳＴＡＮＴＳＵＢＬＩＮＥＯＦＴＨＥＨＵＭＡＮＧＡＳＴＲＩＣＡＤＥＮＯＣＡＲＣＩＮＯＭＡＣＥＬＬＬＩＮＥＷａｎｇＹａｎｐｉｎｇ；王艳萍；ＸｕＧａｎｇ；徐刚（Ｉ...     

GST-π EXPRESSION IN TRANSFORMED CELLS BY TRANSFECTING OF DNA ISOLATED FROM HUMAN FETAL LUNG TISSUES TREATED WITH CARCINOGENS

ＧＳＴπＥＸＰＲＥＳＳＩＯＮＩＮＴＲＡＮＳＦＯＲＭＥＤＣＥＬＬＳＢＹＴＲＡＮＳＦＥＣＴＩＮＧＯＦＤＮＡＩＳＯＬＡＴＥＤＦＲＯＭＨＵＭＡＮＦＥＴＡＬＬＵＮＧＴＩＳＳＵＥＳＴＲＥＡＴＥＤＷＩＴＨＣＡＲＣＩＮＯＧＥＮＳＹａｏＤｅｎｇｇａｏ姚登高ＨｕＧｕ...     

STUDIES ON THE GAP JUNCTIONAL INTERCELLULARCOMMUNICATION OF HUMAN NASOPHARYNGEALCARCINOMA CELLS AND THE EFFECT OF RII

ＳＴＵＤＩＥＳＯＮＴＨＥＧＡＰＪＵＮＣＴＩＯＮＡＬＩＮＴＥＲＣＥＬＬＵＬＡＲＣＯＭＭＵＮＩＣＡＴＩＯＮＯＦＨＵＭＡＮＮＡＳＯＰＨＡＲＹＮＧＥＡＬＣＡＲＣＩＮＯＭＡ　ＣＥＬＬＳＡＮＤＴＨＥＥＦＦＥＣＴＯＦＲＩＩＨａｎＬｉｑｕｎ韩立群；ＧａｏＪｉｎ高进；...     

EVALUATION OF REVERSE PASSIVE HEMAGGLUTINATION （RPHA） FECAL OCCULT BLOOD TEST IN SCREENING OF COLORECTAL NEOPLASIA

ＥＶＡＬＵＡＴＩＯＮＯＦＲＥＶＥＲＳＥＰＡＳＳＩＶＥＨＥＭＡＧＧＬＵＴＩＮＡＴＩＯＮ（ＲＰＨＡ）ＦＥＣＡＬＯＣＣＵＬＴＢＬＯＯＤＴＥＳＴＩＮＳＣＲＥＥＮＩＮＧＯＦＣＯＬＯＲＥＣＴＡＬＮＥＯＰＬＡＳＩＡＹｕＨａｉ；ＺｈｏｕＬｕｎ；ＺｈｅｎＢｅｉｙｉ；Ｑ...     

LOOSENING AND LENGTHENING OF INTESTINAL TRACT AFTER RECTAL ISOLATION IN ANUS－SAVING RESECTION FOR RECTAL CARCINOMA

ＬＯＯＳＥＮＩＮＧＡＮＤＬＥＮＧＴＨＥＮＩＮＧＯＦＩＮＴＥＳＴＩＮＡＬＴＲＡＣＴＡＦＴＥＲＲＥＣＴＡＬＩＳＯＬＡＴＩＯＮＩＮＡＮＵＳ－ＳＡＶＩＮＧ　ＲＥＳＥＣＴＩＯＮＦＯＲＲＥＣＴＡＬＣＡＲＣＩＮＯＭＡＺｈａｎｇＢａｏｎｉｎｇ张保宁；ＹｕＨｏｎｇｔｉ...     

THE EXPRESSION OF CATHEPSIN－D，C－erbB－2 AND EGFR IN BREAST CANCER AND ITS CORRELATION TO LYMPHATIC ME

ＴＨＥＥＸＰＲＥＳＳＩＯＮＯＦＣＡＴＨＥＰＳＩＮ－Ｄ，Ｃ－ｅｒｂＢ－２ＡＮＤＥＧＦＲＩＮ　ＢＲＥＡＳＴＣＡＮＣＥＲＡＮＤＩＴＳＣＯＲＲＥＬＡＴＩＯＮＴＯＬＹＭＰＨＡＴＩＣＭＥＴＡＳＴＡＳＩＳＸｕＬｉａｎｇｚｈｏｎｇ许良中；ＺｈｕＷｅｉｐｉｎｇ朱伟萍；...     

THE IN VITRO POTENTIATION OF LAK CELL CYTOTOXICITY IN CANCER AND AIDS PATIENTS INDUCED BY F3—A FRACTIONATED EXTRACT OF ASTRAG

ＴＨＥＩＮＶＩＴＲＯＰＯＴＥＮＴＩＡＴＩＯＮＯＦＬＡＫＣＥＬＬＣＹＴＯＴＯＸＩＣＩＴＹＩＮＣＡＮＣＥＲＡＮＤＡＩＤＳＰＡＴＩＥＮＴＳＩＮＤＵＣＥＤＢＹＦ３—ＡＦＲＡＣＴＩＯＮＡＴＥＤＥＸＴＲＡＣＴＯＦＡＳＴＲＡＧＡＬＵＳＭＥＭＢＲＡＮＡＣＥＵＳＣｈｕ...     

Prognostic significance of Ki-67 reactivity in soft tissue sarcomas

Proliferative activity of soft tissue sarcomas (STS) in 34 cases was estimated by immunohistochemical procedures (avidin-biotin complex [ABC] method) with monoclonal antibody Ki-67 which reacts with a nuclear antigen expressed in all phases of cell cycle except G0. In 20 of 34 cases (59%), varying numbers of Ki-67-positive tumor cells were detected with a range from 5 to 382 per 10 high power fields (HPF) (mean 57.2/10 HPF). Ki-67 index (the number of Ki-67-positive tumor cells/10 HPF) positively correlated with mitotic count (r = 0.428, P less than 0.02), cellularity (r = 0.447, P less than 0.01), and histologic grade (r = 0.473, P less than 0.01). The Ki-67 low index group (less than 50/10 HPF) showed more favorable prognosis than the high index group (more than 50/10 HPF) (P less than 0.005). Three cases with low mitotic count and unfavorable prognosis were proved to be the Ki-67 high index group (142-382/10 HPF). These results indicated that reactivity of tumor cells for Ki-67 is a useful prognostic marker in the patients with STS, and might be used as one of the histologic factors for the grading of STS.     

乳腺浸润性小叶癌组织Ki-67表达与临床病理特征相关性分析

目的 浸润性小叶癌(invasive lobular carcinoma,ILC)组织中Ki-67表达的研究较少,对其预后预测价值尚需进一步文献支持.本研究探讨ILC组织不同临床病理特征下Ki-67表达差异及其与预后的关系.方法 收集天津医科大学肿瘤医院2003-01-10-2012-12-15收治的381例乳腺ILC患者的临床病理资料,分析Ki-67与其临床病理特征的相关性.分析不同年龄、月经状态、体质量指数、家族史、肿瘤大小、淋巴结状态、病理学分期、组织学分型、ER状态、PR状态、HER-2状态和p53状态下,Ki-67表达与预后的关系.结果 381例ILC组织中Ki-67低表达76例(19.9%),中表达91例(23.9%),高表达214例(56.2%).在不同肿物大小(χ2=12.524,P=0.014)、腋窝淋巴结情况(χ2=6.114,P=0.047)、临床分期(χ2=10.434,P=0.034)、ER表达(χ2=6.339,P=0.041)和组织学类型(χ2=78.288,P<0.001)情况下,Ki-67表达差异有统计学意义.Ki-67表达与肿物大小(r=0.168,P=0.001)、腋窝淋巴结情况(r=0.108,P=0.036)、临床分期(r=0.149,P=0.004)和组织学类型(r=0.532,P<0.001)呈正相关.Ki-67表达与ER表达呈负相关,r=-0.112,P=0.029.在肿瘤大小2~5 cm、有腋窝淋巴结转移及临床Ⅱ期ILC组织中,Ki-67表达对患者总生存(overall survival,OS)差异有统计学意义,P<0.05;而对无病生存(disease-free survival,DFS)差异无统计学意义,P>0.05.Cox多因素分析显示,有无淋巴结转移(P=0.000)是ILC总生存的独立预后因素,而肿瘤大小、临床分期和Ki-67表达水平不是影响ILC总生存的独立预后因素,P>0.05.结论 乳腺ILC组织中Ki-67高表达.就诊时肿物越大、有腋窝淋巴结转移和临床分期越高,Ki-67表达水平越高,而ER表达水平越高,Ki-67表达水平越低,肿物大小2~5 cm、有腋窝淋巴结转移及临床Ⅱ期,即中低度恶性ILC组织中Ki-67表达对患者预后有一定的预测价值,但不是独立预后因素,Ki-67对ILC预后预测作用尚需进一步研究.     

Ki-67在CD117阳性的中、高危险度胃肠道间质瘤中的表达及其意义

 目的　探讨Ki-67在CD117阳性的中、高危险度胃肠道间质瘤（GIST）中的表达及其临床意义。方法　检测Ki-67在CD117阳性的中危险度（GIST）18例、高危险度GIST 25例中的表达,与随访结果对照,并与极低危险度和低危险度组33例比较,分析Ki-67指数（LI）与危险度的关系。结果　中、高危险度组随访40例,其中26例健在,高危组7例、中危组5例死于GIST,另2例死于其他原因。Ki-67 LI> 5 %在危险度中、高组与极低和低组间表达差异有统计学意义（P＜0.01）,Ki-67 LI还与核分裂象计数（MI）（＞5／50 HPF）、肿瘤大小（＞5 cm）相关（P＜0.05）,与部位无关（P＞0.05）。结论　Ki-67 LI＞5 %与肿瘤大小＞5 cm、MI＞5／50 HPF一起可作为CD117阳性的GIST中、高危险度的有用评价指标。     

Prognostic significance of argyrophilic nucleolar organizer staining in soft-tissue sarcomas.

The utility of argyrophilic stain for nucleolar organizer region (AgNOR) for estimating proliferative activity and prognosis of soft-tissue sarcomas (STS) was examined. Formalin-fixed and paraffin-embedded sections of 38 cases with STS were used; the reaction product of AgNOR stain was observed as dots mainly in the nucleoli. The mean number of AgNOR dots per nucleus of tumor cells was calculated in 200 cells (AgNOR count). The AgNOR count, ranging from 1.4 to 16.1 (mean, 7.5), showed a good correlation with cellularity (r = 0.483, p less than 0.003) and histologic grade (r = 0.626, p less than 0.00005), but less shown with mitotic counts (r = 0.350, p less than 0.04). The prognosis of cases with AgNOR low-count group (5-year survival rate was 74.6%) was much better than those in high count group (33.3%) (p less than 0.0005). The AgNOR count correlated well with reactivity of tumor cells for Ki-67 staining, which was available only in freshly prepared sections. These findings suggested that the AgNOR staining is a simple and useful method for estimating tumor-cell proliferation and prognosis of patients with STS.     

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

Primary systemic therapy (PST) for operable breast cancer enables the identification of in vivo biological markers that predict response to treatment. A total of 118 patients with T2-4 N0-1 M0 primary breast cancer received six cycles of anthracycline-based PST. Clinical and radiological response was assessed before and after treatment using UICC criteria. A grading system to score pathological response was devised. Diagnostic biopsies and postchemotherapy surgical specimens were stained for oestrogen (ER) and progesterone (PgR) receptor, HER-2 and cell proliferation (Ki-67). Clinical, radiological and pathological response rates were 78, 72 and 38%, respectively. There was a strong correlation between ER and PgR staining (P < 0.0001). Higher Ki-67 proliferation indices were associated with PgR- tumours (median 28.3%, PgR+ 22.9%; P = 0.042). There was no relationship between HER-2 and other biological markers. No single pretreatment or postchemotherapy biological parameter predicted response by any modality of assessment. In all, 10 tumours changed hormone receptor classification after chemotherapy (three ER, seven PgR); HER-2 staining changed in nine cases. Median Ki-67 index was 24.9% before and 18.1% after treatment (P = 0.02); the median reduction in Ki-67 index after treatment was 21.2%. Tumours displaying >75% reduction in Ki-67 after chemotherapy were more likely to achieve a pathological response (77.8 vs 26.7%, P = 0.004).     

Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study

The number of proliferating cells was determined by Ki-67 antibody in 107 primary breast carcinomas. These results were compared with transferrin receptor (TrfR) expression, estrogen receptor (ER) status, histologic type, tumor grade, size and axillary lymph node status. The percentage of Ki-67-positive cells ranged from 0.9 to 26.4%. The proportion of Ki-67-positive cells was highest in medullary carcinomas. Immunoreactivity of Ki-67 in relation to TrfR expression showed significant correlation (p = 0.0001). An inverse relationship between ER status and Ki-67 positivity existed (p = 0.0001). 88 cases were subjected to histologic grading. There was a significant relationship showing an increase of Ki-67 immunoreactivity with decrease of tumor differentiation (p = 0.0001). The distribution of Ki-67 reactivity in relation to tumor size and nodal status of the axilla revealed positive correlations (p = 0.02; p less than 0.05). In conclusion, the use of Ki-67 monoclonal antibody as a marker for cell proliferation represents a method to get kinetic data inhering prognostic value.     

肾癌细胞Ki-67免疫组化染色指数与预后的关系

 为探索肾癌预后较好的估价指标，41例肾癌根治标本Ki—67免疫组化染色。复发组的Ki—67染色指数显著高于未复发组（P相似文献   

结直肠癌中CDX2、PTEN、Ki-67的表达及DNA倍体分析

目的探讨CDX2、PTEN、Ki-67在结直肠癌中的表达及其与DNA倍体的相互关系。方法采用免疫组织化学SP法检测50例结直肠癌组织和10例癌旁的正常肠黏膜组织中CDX2、PTEN及硒-67的表达,运用流式细胞术（FCM）对50例结直肠癌组织做DNA倍体分析。结果结直肠癌和正常肠黏膜组织CDX2的阳性率分别为82％（41／50）和100％（10／10）,差异有统计学意义（P〈0．05）。PTEN在两组的表达阳性率分别为64％（32／50）和90％（9／10）,差异有统计学意义（P〈0．05）。二者与肿瘤的TNM分期、组织分级、淋巴结转移、原发灶浸润程度相关。CDX2和PTEN与Ki-67呈负相关（r=-0．254,r=-0．340）。二倍体肿瘤中CDX2的表达明显高于异倍体组（93．75％：76．47％）,而PTEN在两组表达中差异无统计学意义。结论CDX2与FFEN呈正相关,二者与Ki-67呈负相关,在调节肠上皮细胞增生分化方面PTEN对CDX2有调控作用。CDX2的下降与肿瘤恶性程度、预后有关。     

乳腺癌组织中E-cad、Ki-67的表达及其与临床病理特征和腋窝淋巴结转移的相关性

目的:通过检测乳腺癌组织中E-cad、Ki-67的表达,探究其与临床病理特征和腋窝淋巴结转移的相关性。方法:回顾性选取2017年05月至2019年12月我院甲乳外科收治的135例女性乳腺癌患者病理资料及石蜡组织做标本。采用免疫组化染色法检测乳腺癌患者组织中E-cad及Ki-67的表达情况;根据腋窝淋巴结转移与否分为转移组和非转移组,分析腋窝淋巴结转移与临床病理及E-cad和Ki-67表达的关系;Pearson检验分析腋窝淋巴结转移与E-cad、Ki-67表达的相关性。结果:135例乳腺癌患者术后病理证实79例发生腋窝淋巴结转移,总转移率为58.5%。免疫组化结果显示,乳腺癌组织中E-cad主要定位于细胞膜,Ki-67主要定位于细胞质和（或）细胞核。135例乳腺癌患者中E-cad阳性表达率为57.8%,Ki-67阳性表达率为68.1%。腋窝淋巴结转移与肿瘤大小、脉管浸润、组织学分级、肿瘤T分期、分子分型、AR、E-cad及Ki-67等显著相关（P＜0.05）。肿瘤大小、脉管浸润、组织学分级、AR、E-cad及Ki-67表达是影响乳腺癌患者腋窝淋巴结转移的危险因素（P＜0.05）。Pearson检验显示E-cad表达与腋窝淋巴结转移呈负相关（r=-0.476,P=0.000）,Ki-67表达与腋窝淋巴结转移呈正相关（r=0.554,P=0.000）。结论:乳腺癌组织中E-cad表达与腋窝淋巴结转移呈负相关,Ki-67表达与腋窝淋巴结转移呈正相关;E-cad低表达与Ki-67高表达在乳腺癌浸润转移过程中可能发挥一定作用,通过检测E-cad及Ki-67表达水平可预测乳腺癌患者腋窝淋巴结转移情况,对判断患者预后具有重要临床意义。     

胶质瘤组织中GRK5和Ki-67的表达情况及临床意义

目的:探讨GRK5和Ki-67在胶质瘤组织中的表达情况,与胶质瘤临床病理特征之间的关系及GRK5和Ki-67在胶质瘤中的预后价值。方法:本研究收集2014年1月至2017年1月我院手术切除的104例脑胶质瘤患者的组织标本及同期因颅内损伤行颅内减压术手术切除的正常脑组织20例,采用免疫组化SP法检测胶质瘤组织及其正常脑组织中GRK5和Ki-67的表达水平。相关分析采用Spearman等级相关分析法。采用卡方检验分析GRK5和Ki-67在胶质瘤组织中的表达与临床病理特征的相关性。生存分析采用Kaplan-Meier和Log-rank 检验,预后分析采用Cox比例风险模型。结果:通过免疫组化检测结果显示,GRK5在104例胶质瘤组织中阳性表达66例,阳性率为63.5%;在20例正常脑组织中阳性表达2例,阳性率为10.0%。Ki-67在104例胶质瘤组织中阳性表达69例,阳性率为66.3%;在20例正常脑组织中阳性表达率为0.0%。通过Spearman等级相关分析得出,胶质瘤组织中GRK5和Ki-67表达呈正相关（r=0.558,P=0.000）。分析GRK5和Ki-67的表达与胶质瘤患者临床病理特征之间的关系,结果显示GRK5和Ki-67的表达与WHO分级有关（P＜0.05）,与患者性别、年龄、肿瘤直径、肿瘤类型无关（P＞0.05）。对104例患者进行生存分析,结果显示GRK5阳性表达患者生存率显著低于阴性表达患者（P=0.033）;Ki-67阳性表达患者生存率显著低于阴性表达患者（P=0.033）。Cox回归模型分析结果显示,GRK5阳性表达和Ki-67阳性表达均是影响胶质瘤患者预后的独立危险因素（P＜0.05）。结论:GRK5和Ki-67与胶质瘤的发生发展及细胞增殖有关,GRK5和Ki-67有可能作为胶质瘤患者的预后标志物及临床检测或联合检测的指标,提高临床诊断率。